Form 4: Alnylam Pharmaceuticals CEO Transfers Shares to Irrevocable Trust

CEO Yvonne Greenstreet transferred 8,376 shares of Alnylam Pharmaceuticals common stock to an irrevocable trust for estate planning purposes.

Summary

• On May 16, 2025, Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, transferred 8,376 shares of common stock to the Yvonne Greenstreet 2024 Irrevocable Trust Dtd 10/29/2024.
• The transfer was a bona fide gift for estate planning purposes.
• Greenstreet is neither the trustee nor a beneficiary of the trust.
• Following the transaction, Greenstreet directly owns 48,948 shares of Alnylam common stock.
• She also indirectly owns 407 shares through a managed account related to the issuer's 401(k) plan.

Sentiment

Score: 7

Explanation: The document itself is neutral as it reports a standard transaction. The sentiment is slightly positive as it reflects personal financial planning by the CEO, which can be seen as a sign of long-term commitment.

Industry Context

This is a routine disclosure of an insider transaction and doesn't necessarily reflect a change in the company's outlook or performance.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on stakeholders as it is a personal financial matter for the CEO and does not affect the company's operations or financial position.

Key Dates

Keywords

Alnylam Pharmaceuticals, Yvonne Greenstreet, stock transfer, Form 4, insider trading, estate planning, irrevocable trust, beneficial ownership